News Headlines Article

As a cure for high drug prices, outcomes-based deals aren’t delivering yet
Modern Healthcare

Facing growing calls for regulating prescription drug prices, the pharmaceutical industry has touted a preferred alternative for making drugs more affordable—private deals in which health plans pay them more or less for a drug depending on how well it works for plan members.

But insurers and independent experts say outcomes-based contracting has made slow and uncertain progress since it was introduced in the past decade, with few if any published results. While it may help on the margins with some drugs, many observers doubt it offers a viable solution to the broad problem of prescription drug affordability in the U.S.